ScreenerHero

BRNS Barinthus Biotherapeutics PLC

NAS · US · Healthcare · Biotechnology · barinthusbio.com
0.7400USD0.00%Mkt Cap: 30.23M $P/E: —

Barinthus Biotherapeutics plc, together with its subsidiaries, engages in the research, development, and commercialization of immunotherapies and vaccines in the United States and the United Kingdom. The company develops…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap30.23M USD
Enterprise Value-18.71M USD
Revenue (TTM)—
Gross Profit8.59M USD
Net Income (TTM)-66.43M USD
Revenue/Share—
Last Price0.7400 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees14
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.65
PEG—
EV/EBITDA0.60
EV/Revenue—
P/S—
P/B0.53
EPS (TTM)-1.02
EPS (Forward)-1.14
52W Range
0.512017% of range1.830
52W High1.830 USD
52W Low0.5120 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-89.52%
ROA-67.67%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-47.98M USD
CapEx (TTM)37.00K USD
FCF Margin—
FCF Yield-20.41%
Net Debt-49.00M USD
Net Debt/EBITDA1.57
Balance Sheet
Debt/Equity0.15
Current Ratio5.54
Quick Ratio5.33
Book Value/Sh1.40 USD
Cash/Share1.45 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)6.000 USD
Upside (mean)+710.8%
Target Range6.000 USD – 6.000 USD
# Analysts1
Ownership
Shares Out.40.85M
Float27.26M
Insiders19.81%
Institutions44.07%
Short Interest
Short Ratio0.3d
Short % Float0.05%
Short % Out.0.03%
Shares Short13.21K
Short (prev mo.)45.91K
Technical
SMA 500.6455 (+14.6%)
SMA 2000.6584 (+12.4%)
Beta-0.36
S&P 52W Chg16.45%
Avg Vol (30d)55.12K
Avg Vol (10d)60.30K
Technical Indicators
RSI (14)62.8
MACD0.0339
MACD Signal0.0335
MACD Hist.+0.0004
BB Upper0.8266 USD
BB Middle0.7006 USD
BB Lower0.5746 USD
BB Width35.97%
ATR (14)0.0337 USD
Vol Ratio (20d)0.00x